Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- Uncovering a key mechanism in assembly of Avian Sarcoma Virus, a relative of HIV-1 on December 18, 2018 at 2:01 pm
BIRMINGHAM, Ala. - A key step in retroviral growth inside a cell, as described by Jamil Saad, Ph.D., and colleagues, is portrayed on the cover of The Journal of Biological Chemistry. It is a visual im... […]
- The plan: Zero new HIV diagnoses in New Jersey by 2025 on December 18, 2018 at 1:58 pm
Down from 1,722 in the middle of last decade, New Jersey saw 1,048 new HIV diagnoses in 2017. Is it possible that number gets down to zero, or close to it, by the year 2025? Health officials and ... […]
- Telling The Stories Of Gay Black Men Can End HIV Stigma on December 18, 2018 at 1:23 pm
While HIV rates spike in Atlanta, Johnnie Ray Kornegay III is seeking to record the stories of Black gay men in pictures. Kornegay’s journey to professional photographer began when he set out to be a ... […]
- Why do patients with HIV have higher rates of cancer? on December 18, 2018 at 1:00 pm
While it has been known for some times that there was an increased risk of cancer for those dealing with HIV, the mechanism behind the link have not been well understood. Enter a new study, published ... […]
- App could let more at-risk people self-test for HIV on December 18, 2018 at 10:50 am
A new app called HIVSmart! lets people test themselves for HIV, connects them to care quickly, and could be adapted for many at-risk populations, according to a new study. The World Health Organizatio... […]
- Get HIV, Hepatitis Tests If This Is Your Dentist: King County on December 18, 2018 at 10:42 am
BURIEN, WA - A dentist office in Burien has been shut down by the state due to poor disinfection and sterilization practices, and King County is advising former patients to get tested for HIV, hepatit... […]
- HIV Community Advocates React to HHS Secretary Azar's Presidential Advisory Council on HIV/AIDS Announcements on December 18, 2018 at 8:56 am
Last week, during the annual National Ryan White Conference on HIV Care and Treatment in National Harbor, Maryland, Health and Human Services (HHS) Secretary Alex Azar announced that after the terms o... […]
- State focuses on most vulnerable in effort to eradicate new HIV cases on December 18, 2018 at 7:29 am
Black women are around 40 times more likely to be diagnosed with HIV than white women, yet many black women said in listening sessions around the state that they aren’t getting that message. This is t... […]
- Rutgers Research Finds Text-Based Counseling May Help Decrease HIV Risk on December 18, 2018 at 7:15 am
Newswise — A mobile app created by a Rutgers researcher could be used to improve the lives of LGBTQ people who lack access to HIV prevention and education. Corina Lelutiu-Weinberger, a Rutgers School ... […]
via Bing News